OBJECTIVE: We sought to estimate the cost-effectiveness of magnesium neuroprophylaxis
for all women at risk for preterm birth< 32 weeks. STUDY DESIGN: A decision analytic and …

The aim of the study was to identify the optimal therapeutic maternal magnesium drug
exposure and maternal serum concentration to prevent cerebral palsy in the extremely …

Intrapartum magnesium for prevention of cerebral palsy: cont... : Current Opinion in Obstetrics
and Gynecology Intrapartum magnesium for prevention of cerebral palsy: continuing …

Available evidence now suggests that magnesium sulfate administered to mothers prior to
early preterm delivery reduces the risk of cerebral palsy in surviving neonates. The …

Cerebral palsy (CP) remains the most significant neurological disorder associated with
preterm birth. It disrupts quality of life and places huge cost burdens on society. Antenatal …

OBJECTIVE: Clinical trials support the efficacy and safety of magnesium sulfate for cerebral
palsy prevention. We evaluated the implementation of a clinical protocol for the use of …

Magnesium sulphate has been demonstrated to be an effective neuroprotectant for babies
delivered prematurely (under 37 weeks' gestational age). Antenatal administration reduces …

Objective To evaluate a slower (compared with a standard) infusion rate of the loading dose
of magnesium sulphate for preterm fetal neuroprotection as a strategy to reduce maternal …

Background The effectiveness of antenatal magnesium sulphate for neuroprotection of the
fetus, infant, and child prior to very preterm birth, when given to women considered at risk of …

Objective: To provide guidelines for the use of antenatal magnesium sulphate (MgSO4) for
fetal neuroprotection of the preterm infant. Options: Antenatal MgSO4 administration should …